U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Ovarian serous cystadenocarcinoma

MedGen UID:
83541
•Concept ID:
C0279663
•
Neoplastic Process
Synonym: Serous ovarian cystadenocarcinoma
 
Monarch Initiative: MONDO:0006046

Definition

A malignant serous cystic epithelial neoplasm arising from the ovary. It is characterized by the presence of glandular, papillary, or solid structures. Psammoma bodies may be present. In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium. In poorly differentiated cases the malignant epithelial cells show anaplastic features. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • Ovarian serous cystadenocarcinoma

Professional guidelines

PubMed

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.
Xiong DD, Qin Y, Xu WQ, He RQ, Wu HY, Wei DM, Zeng JJ, Dang YW, Chen G
Clin Drug Investig 2018 Oct;38(10):909-925. doi: 10.1007/s40261-018-0683-8. PMID: 30097905
Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary.
Geppert M, Smyczek-Gargya B
Gynecol Obstet Invest 1995;39(2):136-40. doi: 10.1159/000292395. PMID: 7737584

Recent clinical studies

Etiology

Social, Genetics and Histopathological Factors Related to Titin (TTN) Gene Mutation and Survival in Women with Ovarian Serous Cystadenocarcinoma: Bioinformatics Analysis.
Gomes FC, Figueiredo ERL, Araújo EN, Andrade EM, Carneiro CDL, Almeida GM, Dias HAAL, Teixeira LIB, Almeida MT, Farias MF, Linhares NA, Fonseca NLD, Pereira YDS, Melo-Neto JS
Genes (Basel) 2023 May 16;14(5) doi: 10.3390/genes14051092. PMID: 37239452Free PMC Article
Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH
Exp Biol Med (Maywood) 2022 Jun;247(11):910-920. Epub 2022 Mar 12 doi: 10.1177/15353702221083254. PMID: 35285286Free PMC Article
Ancestry-specific predisposing germline variants in cancer.
Oak N, Cherniack AD, Mashl RJ; TCGA Analysis Network, Hirsch FR, Ding L, Beroukhim R, Gümüş ZH, Plon SE, Huang KL
Genome Med 2020 May 29;12(1):51. doi: 10.1186/s13073-020-00744-3. PMID: 32471518Free PMC Article
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.
Xiong DD, Qin Y, Xu WQ, He RQ, Wu HY, Wei DM, Zeng JJ, Dang YW, Chen G
Clin Drug Investig 2018 Oct;38(10):909-925. doi: 10.1007/s40261-018-0683-8. PMID: 30097905
Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
Cho SY, Kim K, Park MS, Jang MY, Choi YH, Han S, Shin HM, Chung C, Han HY, Yang JB, Ko YB, Yoo HJ
Oncol Rep 2017 May;37(5):2620-2632. Epub 2017 Mar 21 doi: 10.3892/or.2017.5517. PMID: 28339095Free PMC Article

Diagnosis

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705
Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy.
Ma C, Zheng Q, Wang Y, Li G, Zhao M, Sun Z
Aging (Albany NY) 2023 Aug 21;15(17):8664-8691. doi: 10.18632/aging.204968. PMID: 37606975Free PMC Article
The circular RNA expression profile in ovarian serous cystadenocarcinoma reveals a complex circRNA-miRNA regulatory network.
Zhuang M, Zhao J, Wu J, Fu S, Han P, Song X
BMC Med Genomics 2021 Dec 2;14(Suppl 2):276. doi: 10.1186/s12920-021-01132-5. PMID: 34857007Free PMC Article
Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
Liu H, Wang A, Ma Y
Biomed Res Int 2020;2020:1392674. Epub 2020 Nov 25 doi: 10.1155/2020/1392674. PMID: 33299855Free PMC Article
Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
Ha M, Kim J, Park SM, Hong CM, Han ME, Song P, Kang CD, Lee D, Kim YH, Hur J, Oh SO
Genet Test Mol Biomarkers 2020 Mar;24(3):145-149. Epub 2020 Feb 27 doi: 10.1089/gtmb.2019.0185. PMID: 32105524

Therapy

Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH
Exp Biol Med (Maywood) 2022 Jun;247(11):910-920. Epub 2022 Mar 12 doi: 10.1177/15353702221083254. PMID: 35285286Free PMC Article
Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z, Zhao Q, Lv B, Qu X, Han X, Wang H, Qiu J, Hua K
Clin Transl Med 2021 May;11(5):e399. doi: 10.1002/ctm2.399. PMID: 34047476Free PMC Article
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome.
Wang S, Jia J, Liu D, Wang M, Wang Z, Li X, Wang H, Rui Y, Liu Z, Guo W, Nie J, Dai H
Sci Rep 2019 Aug 12;9(1):11677. doi: 10.1038/s41598-019-47871-5. PMID: 31406154Free PMC Article
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.
Xiong DD, Qin Y, Xu WQ, He RQ, Wu HY, Wei DM, Zeng JJ, Dang YW, Chen G
Clin Drug Investig 2018 Oct;38(10):909-925. doi: 10.1007/s40261-018-0683-8. PMID: 30097905
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival.
Ursic-Vrscaj M, Bebar S, Zakelj MP
Menopause 2001 Jan-Feb;8(1):70-5. doi: 10.1097/00042192-200101000-00012. PMID: 11201519

Prognosis

ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Li YK, Gao AB, Zeng T, Liu D, Zhang QF, Ran XM, Tang ZZ, Li Y, Liu J, Zhang T, Shi GQ, Zhou WC, Zou WD, Peng J, Zhang J, Li H, Zou J
J Transl Med 2024 Jan 11;22(1):46. doi: 10.1186/s12967-023-04819-8. PMID: 38212795Free PMC Article
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
Wang Y, Zhang Y, Wang F, Li T, Song X, Shi H, Du J, Zhang H, Jing H, Han J, Tong D, Zhang J
Sci Rep 2022 Nov 2;12(1):18518. doi: 10.1038/s41598-022-21328-8. PMID: 36323715Free PMC Article
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
Fäldt Beding A, Larsson P, Helou K, Einbeigi Z, Parris TZ
BMC Cancer 2022 Mar 25;22(1):322. doi: 10.1186/s12885-022-09371-0. PMID: 35331169Free PMC Article
Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
Liao C, Wang A, Ma Y, Liu H
Medicine (Baltimore) 2021 Oct 8;100(40):e27473. doi: 10.1097/MD.0000000000027473. PMID: 34622876Free PMC Article
Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
Liu H, Wang A, Ma Y
Biomed Res Int 2020;2020:1392674. Epub 2020 Nov 25 doi: 10.1155/2020/1392674. PMID: 33299855Free PMC Article

Clinical prediction guides

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705
Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients.
Abouhashem N, Harb O, Elwan A, Zaitoun M, Saraya Y
Pol J Pathol 2022;73(2):120-133. doi: 10.5114/pjp.2022.120097. PMID: 36345952
Clinical Characteristics in the Prediction of Posttreatment Survival of Patients with Ovarian Cancer.
Lu L, Ji S, Jiang J, Yan Y
Dis Markers 2022;2022:3321014. Epub 2022 May 5 doi: 10.1155/2022/3321014. PMID: 35571616Free PMC Article
Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH
Exp Biol Med (Maywood) 2022 Jun;247(11):910-920. Epub 2022 Mar 12 doi: 10.1177/15353702221083254. PMID: 35285286Free PMC Article
Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
Liu H, Wang A, Ma Y
Biomed Res Int 2020;2020:1392674. Epub 2020 Nov 25 doi: 10.1155/2020/1392674. PMID: 33299855Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...